Rebamipide

Overview

Rebamipide (OPC12759) is an orally active gastroprotective agent that enhances the production of endogenous PGs (especially intragastric PGE2 ) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide exerts anti-proliferative activity against gastric cancer cells. Rebamipide can be used in studies of mucosal protection, gastroduodenal ulcer, gastritis and gastric cancer .

Application

Products | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Gastric Cancer | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > COX

Product Information

• Catalog No.: HY-B0360
• CAS No.: 90098-04-7
• Molecular Formula: C19H15ClN2O4
• Molecular Weight: 370.79
• Purity: 99.74%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 2.5 mg/mL (6.74 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source